Revive Appoints Infectious Disease Expert As Scientific Adviser

Revive Therapeutics (CSE: RVV) this morning announced that they have appointed Dr David Boulware as scientific advisor, aimed at assisting the company with its previously announced work on infectious diseases.

Boulware is expected to guide Revive on its current and future clinical programs, which includes the research and development strategy for infectious diseases. Boulware is an infectious disease physician-scientist, and is notably the principal investigator of a COVID-19 clinical trial that is looking at hydroxychloroquine and its post-exposure effects on coronavirus (ClinicalTrials.gov Identifier: NCT04308668).

Currently Professor of Medicine, Division of Infectious Diseases and International Medicine at The University of Minnesota, Boulware is primarily focused on meningitis, with his latest research involving improving the clinical outcomes of HIV-infected persons with cryptococcal meningitis and TB meningitis. Currently, Boulware serves on the United Nations and World Health Organization’s health panels for cryptococcal meningitis, as well as the WHO’s panel for advanced HIV disease.

I am excited to assist Revive in their objective in pursuing the clinical development of Bucillamine for infectious diseases and its prospect as a potential solution for COVID-19.

Dr. David Boulware, MD, MPH, CTropMed, FIDSA

Revive Therapeutics previously announced that it is exploring the use of Bucillamine as a potential treatment for infectious diseases, and that is has filed for a provisional patent in the US entitled “Use of Bucillamine in the Treatment of Infectious Diseases” (Serial No. 62/991,996).

Revive Therapeutics last traded at $0.08 on the CSE.


FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

How to Still Find 10-Bagger Gold and Silver Stocks | Don Durrett

First Majestic Silver: Jerritt Canyon Is BACK!

Canada May Finally Be Backing Its Battery Supply Chain | John Passalacqua – First Phosphate

Recommended

Antimony Resources Expands Footprint as Soil Sampling Lights Up Ground South of Bald Hill

Mercado Drills 256 g/t Silver Over 6.5 Metres In First Drill Hole of Inaugural Program

Related News

Blackrock Urged to Divest Chinese Companies due to China’s Human Rights Abuses, Poor Response to Coronavirus

It seems that Donald Trump’s recent demand for the US federal employee retirement fund to...

Friday, May 15, 2020, 07:30:45 AM

Demand for US Oil Could Collapse Once Again as Threat of Second Coronavirus Wave Becomes Imminent

The demand for US oil hit a disastrous low during the onset of the coronavirus...

Sunday, June 28, 2020, 12:39:00 PM

Revive Selects Pharm-Olam As Contract Research Organization For Infectious Disease Study

This evening, Revive Therapeutics (CSE: RVV) announced that the company has signed with a contract...

Wednesday, March 25, 2020, 06:13:35 PM

US COVID-19 Death Toll Surpasses 200,000 as Country Braces for Third Wave

As the US rushes to manufacture and approve a coronavirus vaccine, the number of infections...

Tuesday, September 22, 2020, 06:15:30 PM

Hyperinflation: Remember, GDP = Money Supply x Velocity

When trying to wrap my head around economics, I like to simplify basic principles down...

Saturday, April 4, 2020, 01:45:58 PM